Spots Global Cancer Trial Database for allogeneic stem cell transplant
Every month we try and update this database with for allogeneic stem cell transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00186823 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Lymphoma, Non-H... Myelodysplastic... | Miltenyi Biotec... Stem Cell Trans... TBI, systemic c... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil | NCT05256537 | Hematologic Neo... | Omission of the... | 18 Years - 75 Years | Cedars-Sinai Medical Center | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) | NCT03419078 | Allogeneic Stem... Graft Versus Ho... Hematologic Mal... Stem Cell Trans... | 17 Years - | Imperial College Healthcare NHS Trust | ||
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders | NCT00587054 | Allogeneic Stem... Leukemia Non-Hodgkins Lymphoblastic L... Myelodysplastic... Paroxysmal Noct... | cytoreductive r... | 18 Years - 55 Years | Memorial Sloan Kettering Cancer Center | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | NCT03885947 | Hematological M... Acute Leukemia ... Acute Lymphobla... Myelodysplastic... Non-Hodgkin Lym... Hodgkin Lymphom... | Cord blood stem... Valproic Acid Fludarabine cytoxan Thiotepa TBI | 18 Years - 65 Years | Icahn School of Medicine at Mount Sinai | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | NCT01611298 | Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Hodgkin Lymphom... Non-Hodgkin Lym... | Tetanus | 3 Years - 70 Years | Baylor College of Medicine | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors | NCT02301065 | Hematologic Mal... | - 21 Years | St. Jude Children's Research Hospital | ||
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Autologous and Allogeneic Transplant for Relapsed Lymphoma | NCT00802113 | Non-Hodgkin's L... Hodgkins Diseas... | Fludarabine Busulfan Anti-Thymocyte ... | - 55 Years | Columbia University | |
| Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | NCT00369226 | Hematologic Mal... | Bortezomib (Vel... Tacrolimus Methotrexate blood stem cell... | 18 Years - | Dana-Farber Cancer Institute | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01027000 | Leukemia Lymphoma | rituximab busulfan cyclophosphamid... fludarabine pho... methotrexate sirolimus tacrolimus allogeneic stem... | 18 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01326728 | Chronic Myeloge... Acute Myelogeno... Acute Lymphobla... Hodgkins Lympho... Non-Hodgkins Ly... | Allogeneic stem... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease | NCT02172768 | Acute Graft Ver... Allogeneic Stem... Acute Myeloid L... Myelo Dysplasti... | alternate dosin... daily dosing micafungin | 18 Years - | Radboud University Medical Center | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia | NCT06058572 | Acute Leukemia | Rifaximin with ... Allogeneic stem... | 18 Years - 70 Years | Tata Memorial Centre | |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | NCT00579111 | Myelodysplastic... Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Plasma Cell Dys... Lymphoprolifera... Hematologic Dis... | Campath Busulfan Fludarabine Hematopoietic s... FK-506 | - 70 Years | Baylor College of Medicine | |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | NCT01611298 | Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Hodgkin Lymphom... Non-Hodgkin Lym... | Tetanus | 3 Years - 70 Years | Baylor College of Medicine | |
| Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | NCT00355407 | Hematologic Mal... | Darbepoetin alf... | 18 Years - | Dana-Farber Cancer Institute | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00525876 | Lymphoma | Cyclophosphamid... Fludarabine Rituximab Alemtuzumab Allogeneic Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | NCT04361058 | Leukemia, Myelo... Myelodysplastic... Myelodysplastic... | Nivolumab | 18 Years - 65 Years | SCRI Development Innovations, LLC | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Autologous and Allogeneic Transplant for Relapsed Lymphoma | NCT00802113 | Non-Hodgkin's L... Hodgkins Diseas... | Fludarabine Busulfan Anti-Thymocyte ... | - 55 Years | Columbia University | |
| Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease | NCT02172768 | Acute Graft Ver... Allogeneic Stem... Acute Myeloid L... Myelo Dysplasti... | alternate dosin... daily dosing micafungin | 18 Years - | Radboud University Medical Center | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | NCT00529360 | Acute Lymphobla... Acute Myelogeno... | Clofarabine Clofarabine | - 30 Years | New York Medical College | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant | NCT02611063 | Hematological M... | fostamatinib | 18 Years - | Duke University | |
| Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia | NCT06058572 | Acute Leukemia | Rifaximin with ... Allogeneic stem... | 18 Years - 70 Years | Tata Memorial Centre | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years | NCT00546988 | Multiple Myelom... | allogeneic stem... | 18 Years - 60 Years | University of Wuerzburg | |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | NCT04361058 | Leukemia, Myelo... Myelodysplastic... Myelodysplastic... | Nivolumab | 18 Years - 65 Years | SCRI Development Innovations, LLC | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | NCT02477878 | Leukemia Myelodysplastic... Lymphoma Multiple Myelom... Hematologic Neo... | BPX-501 Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies | NCT02321345 | Malignancies, H... | Palliative Care... | 18 Years - | Medical College of Wisconsin | |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | NCT06398457 | Hematologic Mal... Bone Marrow Tra... Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Multiple Myelom... Aplastic Anemia Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myeloid... Myelofibrosis | Darzalex Faspro... JH-DSA Semi-Qua... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections | NCT02805946 | Allogeneic Stem... Acute Graft Ver... Acute Myeloid L... Myelo Dysplasti... | posaconazole | 18 Years - | Radboud University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
